cystic fibrosis

An earlier diagnosis and treatment of nontuberculous mycobacteria (NTM) infection in patients with cystic fibrosis (CF) may positively affect the patient’s lung function, a study suggests. NTM are a group of bacterial species, found in soil and water, which are not usually associated with human disease, except if they infect…

The adaptation of bacteria Pseudomonas aeruginosa to the lungs of cystic fibrosis (CF) patients may make them more susceptible to antibiotics and easier to kill, according to new research. The study with that finding, “Evolutionary trade-offs associated with loss of PmrB function in host-adapted Pseudomonas aeruginosa,”…

Treating cystic fibrosis (CF) patients with the antibiotic azithromycin in addition to vitamin E supplements did not change their oxidative stress status in a pilot study, researchers report. These results were published in the journal Frontiers in Pharmacology, in the article “Metabolomic Analysis by Nuclear Magnetic Resonance…

Adding azithromycin to the standard antibiotic treatment for early Pseudomonas aeruginosa infections is associated with fewer pulmonary exacerbations in children with cystic fibrosis (CF), results from a Phase 3 trial show. Trial findings were published in the study, “Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis: The Optimize Randomized…

The Mike McMorris Cystic Fibrosis Research and Care Center, part of the Children’s Hospital Colorado, is one of the 82 clinical sites involved in the Phase 3 clinical trial that is assessing the efficacy of VX-659 in a triple combination with Symdeko (tezacaftor/ivacaftor and ivacaftor). The…

People ages 12 and older with cystic fibrosis (CF) who live in Canada can now be treated with Vertex Pharmaceuticals’ Symdeko (tezacaftor/ivacaftor and ivacaftor). This follows Health Canada‘s approval of Symdeko to treat people who have two copies of the F508del mutation in the CFTR…

AIT Therapeutics will present new research on the use of inhaled nitric oxide in the treatment of Mycobacterium abscessus lung infections at an upcoming conference, the company recently announced. Data from lab studies and a compassionate use study will be presented at the 3rd Annual World Bronchiectasis Conference July…

A potential therapy delivered through nanoparticles enables production of the normal, healthy form of the key CFTR protein in cystic fibrosis (CF), a new study suggests. The research, “Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis,” was published in the journal Molecular…

Cystic fibrosis (CF), once an exclusively pediatric disease, is clearly one no longer. Of the 32,000 or so Europeans registered with CF, nearly half are more than 18 years old, and babies born with the illness today can expect to live into their 50s and 60s. This means issues like…

Exercise clearly benefits kids with cystic fibrosis (CF), yet these children often lack the motivation to swim, run, box, play football or lift weights. A British healthcare conglomerate says it has found a way to get these kids moving — at no cost to them or their families. Nuffield…